Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Mixed substance
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Mixed substance
Emergency use authorization Experimental Antiviral Jan/23/2023
T cells
Mixed substance
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Remdesivir
Mixed substance
Approved by FDA Experimental Antiviral Jan/18/2023
Mesenchymal stem cells
Mixed substance
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Anti-spike nanobody-IFN-β conjugated exosomes
Mixed substance
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/26/2022
IMAT-MSCs
Mixed substance
Potential treatment - pre-clinical evidence Experimental Other treatment Sep/23/2022
Exosomal vaccine
Mixed substance
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/29/2022
EXO-CD24
Mixed substance
Potential treatment - clinical evidence Experimental Other treatment Jul/13/2022
Bamlanivimab
Mixed substance
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
Mixed substance
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
Mixed substance
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
Ad26.COV2.S
Mixed substance
Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
Mixed substance
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
Mixed substance
Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
Mixed substance
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
Mixed substance
Emergency use authorization Experimental Antiviral Jun/18/2022
REGEN-COV
Mixed substance
Emergency use authorization Experimental Antiviral Jun/03/2022
Convalescent plasma
Mixed substance
Emergency use authorization Experimental Antiviral May/16/2022
ACE2‐Fc
Mixed substance
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022